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1. Introduction 
Glycosylation is an important and highly regulated mechanism of secondary protein 
processing within cells. It plays a critical role in determining protein structure, function and 
stability. Structurally, glycosylation is known to affect the three dimensional configuration 
of proteins. This is of particular importance when considering protein-protein interactions 
such as those that occur between protein ligands and their cognate receptors or in the 
creation of other large macromolecular complexes. Many secreted proteins, such as 
hormones or cytokines, are glycosylated and this has been shown to impact in determining 
their activity when bound to receptors. Changes in these complexes result in alterations in 
how they recruit, interact and activate signaling proteins (e.g. G proteins). Additionally, 
signaling proteins are also glycosylated and this has distinct effects on their function. 
Ultimately, these effects help determine which signaling pathways are activated within the 
cell (Figure 1). Thus, glycosylation plays a key role in determining the cellular response to 
exogenous factors. This chapter will provide an overview of how glycosylation of ligands, 
their receptors, and signaling proteins affects signal transduction in mammalian cells by 
discussing specific examples of how receptor signaling is regulated by glycosylation.  
2. Role of glycosylation in protein function 
Although carbohydrates added to proteins are known to be highly flexible and mobile 
within the constraints of the glycoprotein, they are known to provide a key stabilizing force 
for proteins within their microenvironments. Of particular importance is the role that 
carbohydrates play in achieving the proper three dimensional conformation of 
glycoproteins(1, 2). As the carbohydrates are added to the nascent protein within the 
endoplasmic reticulum, carbohydrates (monosaccharides) are added to the protein on 
specific amino acid residues. Glycosylation has been reported on 8 different amino acids 
with the most common residue for carbohydrate addition being asparagine (N-
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glycosylation). This process can aid in the final protein product folding correctly into its 
three dimensional, biologically active conformation. However, this is not the case for all 
glycoproteins although it has been noted for a significant number (2). Interestingly the 
mechanism of adding these sugar residues is complex and not fully understood but is 
known to require several enzymes and is physiologically regulated. This suggests that 
glycosylation, as well as other secondary protein processing, is vital to the biological 
function of these proteins.  
 
Figure 1. Regulation of receptor-ligand signaling by glycosylation. Glycosylation occurs at every level 
of the receptor signaling mechanism and therefore can impact the biological responses induced by 
receptor-ligand binding. Glycosylation (black lines) can occur on the ligand itself, the receptor, as well 
as on key signaling enzymes and effector proteins (hexagon,triangle). All of which play an improtant 
role in driving the biological responses in the cell. 
In addition to its effects on driving correct folding of glycoproteins, glycosylation also has 
other effects on the physicochemical properties of these proteins. These effects help to 
determine the glycoprotein’s overall energy and this can affect many of the biological 
functions that the protein performs (for a more detailed review see (3)). For example, 
glycosylation is well known to play a role in modulating thermostability of proteins as well 
as the overall charge. Of particular interest to the development of new therapies is the role 
that glycosylation plays in affecting protein-protein interactions. Intermolecular association 
that occur between protein ligands and their cognate receptors or between activated 
receptors and their intracellular signaling machinery have been shown to be modulated by 
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the presence of glycosylation (4). Many examples exist that suggest that glycosylation of 
either a receptor or its ligand aids in determining the resulting biological responses. The 
primary mechanism for these effects lies in the ability of carbohydrates to modulate the 
overall energy state of the protein (2, 3). 
In terms of thermostability, studies of various glycoproteins have focused on the 
thermodynamics of select placement or displacement of glycosylation on proteins (2). 
These studies have revealed that addition of even a single monosaccharide to a protein 
can significantly impact the fluctuation of that protein between folded and unfolded states 
(3). Through detailed NMR evaluation and use of statistical tools it has been found that 
certain commonalities exist for the placement of carbohydrates on protein and predict a 
functional role for these sites in stabilization of protein structures. One such study has 
found that glycosylation can occur on almost any part of a protein’s structure but that 
bends or turns in the structure are preferred. Similarly, it has been found that 
glycosylation of proteins has a greater impact at less structured regions of a protein highly 
suggest that glycosylation plays a key role in protein stabilization (2, 3). In addition to 
aiding the stablization of proteins in a microenvironment, glycosylation has also been 
found to play a key role in stabilizing glycoproteins in the macroenvironment through 
alteration in half-life. There are numerous reports that the presence of polysaccharides 
added as secondary protein processing prolongs the half-life of these proteins including 
antibodies, hormones and cytokines (5). 
3. Role of glycosylation in receptor function 
3.1. Viral coat proteins 
One of the best studied glycoproteins is the HIV viral coat protein, GP120. The description 
of the role of viral glycoproteins in host-virus interactions have been studied extensively 
and reviewed in detail elsewhere (5). However, this important interaction deserves mention. 
The GP120 protein is integral to the initiation of contact between the HIV virus particle and 
its host cell by mediating the adhesion of the viral particle to the host cell surface. It is a 
heavily glycosylated protein owing nearly half of its mass to the presence 27 glycosylated 
residues (5). This protein acts as part of a co-receptor complex with the host cell CD4 
protein. Association between CD4 and GP120 leads to conformational changes in these 
proteins that ultimately lead to membrane fusion between the host cell and the virus 
particle. The presence of this glycosylation acts as a natural barrier to defending immune 
cells and antibodies such that it is difficult for the natural immune system to recognize and 
target the HIV virus for elimination.  
3.2. Interleukins 
Interleukins are secreted glycoproteins of the immune system  that communicate both 
positive and negative regulatory signals to the various cellular and components that make 
up the innate and acquired immune responses. Interleukins and other cytokines exert 
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their actions on their target cells through interactions with specific receptors. Most 
cytokines like interleukins are found in their mature state as glycosylated proteins. In the 
case of these important glycoprotein modulators, both N-linked and O-linked 
glycosylation has been described (6). The role of glycosylation in affecting cytokine 
function has been of interest from both the protein ligand and the receptor perspectives. 
Due to the large number of different cytokines, for the purposes of this chapter we will 
focus on Interleukin 5 (IL5).  
IL5 is an important immune cytokine that is released from T-cells and induces activated B-
cells into antibody producing cells. In addition, IL5 also acts as a differentiating factor for 
eosinophils. From a clinical perspective, the role of IL5 is important for immune diseases 
that involve hyperproliferation and invasion of eosinophils, such as in asthma (7). IL5 works 
as a homodimer that binds specifically to its membrane-bound receptor (IL5R). In the case of 
IL5, chemical digestion of either the N-linked or O-linked sugar residues on recombinant 
hIL5 had profound effects on the biological activity of the cytokine in terms of its ability to 
stimulate release of IgM from BCL1 cells (8). Removal of the N-linked glycosylation on IL5 
improved potency of the cytokine by approximately 3 fold. Interestingly, removal of the O-
linked sugars led to an approximate 10 fold  improvement in potency of IL5 which was 
equivalent to fully deglycosylated IL5 (8). In this same study, the authors also demonstrate 
that the N-linked glycosylation but not the O-linked glycosylation significantly improved 
the thermostability of IL5 in vitro. These data suggest that both N-linked and O-linked 
glycosylation play important roles in the biological activity of IL5.  
The IL5R is composed of two subunits, the IL5R and βc subunits. Mechanistic studies have 
revealed that IL5 induces biological activity through a two step process in which IL5 binds 
to the IL5 subunit leading to interaction with the preformed βc subunit (9, 10). The βc then 
induces the signaling cascade within the target cell through activation of a kinase cascade by 
way of associated JAK kinases. The IL5 subunit is highly glycosylated having 4 N-
glycosylation sites (Asn15, Asn111, Asn196 and Asn224) in the extracellular region (11, 12). 
Complete removal of the glycosylation of IL5 leads to a loss of ligand binding. More 
detailed studies of the contributions of the N-glycosylation sites on IL5 revealed that Asn196 
is required for ligand binding (9). Loss of the other three sites by mutation had no effect on 
IL5 affinity and biological activity (B-cell proliferation assay). Interestingly, mutation of 
Asn196 led to a complete loss of binding and biological activity, suggesting that glycosylation 
of that residue is absolutely required for IL5 recognition (9). 
IL5R βc subunit is also glycosylated. This protein interacts with a number of cytokine 
receptors including  IL5, interleukin 3  (IL3 ) and granulocyte-macrophage colony- 
stimulating factor  (GM-CSF ). Therefore, the βc protein is a common signal transducing 
partner to many cytokine receptors. The βc protein contains an N-linked glycosylation  site 
at Asn328. Conflicting reports have been published suggesting that glycosylation of Asn328 is 
either required for signaling activity of the βc subunit or not required. However, a recent 
publication by Murphy et al, suggests strongly that glycosylation at Asn328 does not play a 
role in either ligand binding or receptor activation. 
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3.3. Glycoprotein hormone family 
The reproductive hormones called gonadotropins (luteininzing hormone (LH) and follicle-
stimulating hormone (FSH)) are important to proper regulation of reproduction. These 
proteins are found in the circulation as alpha subunit and beta subunit heterodimers that 
contain multiple glycosylation sites on both subunits (13, 14). Along with the thyroid-
stimulating hormone (TSH), they comprise the glycoprotein hormone family. Interestingly, 
the degree of glycosylation added to these hormones varies depending upon the 
physiological state and therefore, they are found in the plasma as a series of isoforms that 
vary in glycosylation complexity. 
Historically, it has been accepted that glycosylation complexity has an impact on the overall 
acidity of each isoform with more complex variants (higher degree of terminal sialylation 
and sulfation) possessing more acidic isoelectric points (pI) (15, 16) with less terminally 
sialylated /sulfonated isoforms more basic in pI. Chromoatofocusing has been used as a way 
of purifying these differently glycosylated isoforms. Recently though, Bousfield has 
generated data demonstrating that chromatofocusing does not separate isoforms on the 
basis of glycan structure suggesting that the isoelectric point of gonadotropins is not 
completely determined by the glycosylation structure (17). Nevertheless, the physiological 
significance of these glycosylated variants is suggested by data demonstrating that the 
degree of glycosylation that occurs within the anterior pituitary synthetic cells is regulated 
by exogenous factors including ovarian steroids (18, 19). Tight regulation of this secondary 
protein processing of glycoprotein hormones suggests an important physiological role for 
the presence of glycosylated variants of TSH, LH and FSH. Numerous reports have detailed 
the effects of partial or complete deglycosylation on action of these hormones (14, 20, 21). 
The data in this area are varying with some noting no effects on binding (14, 22-24) and 
others noting increased binding affinity (21, 25). However, recent work in this area using 
more sophisticated separation techniques strongly suggest that hormone glycosylation does 
play a significant role in receptor binding (25). There is a significant effect on signaling. 
Indeed, using a baculovirus expression system to create partially glycosylated isoforms of 
FSH has shown that glycosylation can change the pharmacological properties of the 
hormone via alterations in interaction of the FSH receptor with the G protein signaling 
machinery (13, 24). In addition, numerous reports have found a distinct difference in the 
observed bioactivity of basic isoforms of glycoprotein hormones as compared to acidic 
isoforms (13, 14). 
The glycoprotein hormone receptors are G protein-coupled receptors (GPCR) (26). These 
receptors are characterized by long amino-terminal extracellular domains (>300 aa) that are 
required for binding of ligand, seven lipophilic, membrane-spanning domains and relatively 
short, cytoplasmic carboxy-terminal tails (27, 28). The extracellular domains of the 
glycoprotein hormones are characterized by numerous leucine rich repeats (LRR) that have 
been shown to be important to binding of the receptors to their respective ligands (27). 
Similar to their hormone ligands, glycoprotein hormone receptors also contain sugar 
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residues on their extracellular domains. Studies of the contribution of this glycosylation via 
mutation of the Asp residues acting as glycosylation sites has found that the glycosylation is 
responsible for proper folding of the receptor during protein synthesis (29, 30). This is more 
so for TSHR and FSHR than for LH/hCGR (31). Overall, the glycosylation state of the 
receptor does not seem to have an  effect on ligand binding affinity or activation of signal 
transduction pathways (32). 
4. Glycosylation of signaling proteins  
4.1. Adenylate cyclase 
In addition, to determining ligand-receptor interactions in some systems, glycosylation 
can also play a role in regulating intracellular signaling proteins. Adenylate cyclase is a 
key enzyme that produces the second messenger cAMP from ATP. It is best described for 
its ability to be stimulated or inhibited by activation of  heterotrimeric GTP binding 
proteins (G-proteins) following G-protein-coupled receptor (GPCR) binding to agonist. 
There are nine recognized adenylate cyclase isoforms and three general classes of 
membrane bound adenylate cyclases: the calcium activated family (AC1, AC3 and AC8) , 
the calcium-inhibited family (AC5 and AC6) and the G-protein activated family (AC2, 
AC4 and AC7) (33). All nine adenylate cyclases are regulated by Gs and magnesium. The 
calcium activated family members respond to calcium in a calmodulin-dependent manner 
(33). The calcium-inhibited adenylate cyclases are inhibited by calcium at less than 
micromolar concentrations. The G-protein activated family responds to activation by G βγ 
subunits following GPCR agonist binding (33). In addition, splice variants of some forms 
of adenylate cyclases have been noted (34). Generally speaking, adenylate cyclases tend to 
be clustered together within cell membranes with other signaling components such as 
receptors and G-proteins in lipid rich domains such as those formed by the scaffolding 
protein caveolin-1 (35). 
Several types of post-translational modifications to adenylate cyclases have been found to 
affect their activity; including nitrosylation, phosphorylation and glycosylation (36). In 
terms of glycosylation, regulation of several adenylate cyclase family members has been 
reported. N-linked glycosylation has been observed on the extracellular domains of some 
adenylate cyclases and for this reason there had been some controversy concerning the 
functional role it played in enzyme activity. This was mainly due to the fact that adenylate 
cyclase interacts with its protein partners within domains found on the cytoplasmic side of 
the enzyme. However, deglycosylation using metabolic inhibitors or site-directed mutants 
have revealed a critical role for glycosylation in adenylate cyclase activity.  
Glycosylation of Type 8 adenylate cyclase (AC8) has been found on two of its three 
isoforms (34). These glycosylation sites are found the extracellular surface of two of these 
isoforms (AC8-A and AC8-C) but not on the AC8-B isoform. This is presumably due the 
excision of a portion of the extracellular domain between transmembrane spans 9 and 10 
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in this isoform that contains the N-linked glycosylation site. Recent studies of the role of 
these glycosylation sites in AC8 have shown that they are critical to localization of the 
enzyme to the lipid rich rafts in membranes (37). Thus, potentially determining function 
of AC8 in cells where it is expressed. This would imply a differential localization and 
functional role for AC8-B. 
Glycosylation of AC6 is required for response to several stimulators of AC activity since 
mutagenesis or glycosylation inhibitors affect AC6 response to forskolin and G-proteins (38). 
The other member of the calcium-inhibited ACs, AC5, has two putative glycosylation sites 
but it is still unclear as to whether these sites are glycosylated (36). 
The other member of the adenylate cyclase family of enzymes is adenylate cyclase 9 (AC9). 
This particular adenylate cyclase is the most divergent in terms of sequence from the other 
known ACs. AC9 activity is regulated by G-proteins and by protein kinase C. Gs stimulates 
activation of AC9, while Gi and PKC have been shown to negatively regulate AC9. AC9 is 
glycosylated on two sites; removal of the N-linked glycosylation on these sites by site 
directed mutagenesis did not affect the stimulation of AC9 by forskolin (39). However, 
removal of the glycosylation sites on AC9 did affect Gs -mediated stimulation of AC9 in 
HEK cells (39). 
Taken together, these data reveal an integral role for glycosylation in determining and 
modulating adenylate cyclase localization, protein-protein interactions and function. 
4.2. Insulin receptor signaling 
The insulin receptor is a hetero-tetrameric receptor tyrosine kinase that is well known for its 
regulation of glucose metabolism. The insulin receptor contains numerous glycosylation 
sites that include both O- and N-linked glycosylation. The glycosylation of the insulin 
receptor is metabolically regulated since glucose deprivation has been shown to 
preferentially affect O-linked but not N-linked glycosylation of the receptor. Since insulin is 
a master metabolic regulator, this suggests that glycosylation plays a significant 
physiological/pathophysiological role in insulin action (40). Indeed, mutational analysis of 
the potential O-glycosylation sites on the insulin receptor has revealed significant effects on 
functioning of the receptor. This may be due to the fact that these sites tend to be near 
phosphorylation sites on the receptor important to regulation of the receptor activity (41). 
Removal of glycosylation on the receptor does not affect receptor binding but partial loss of 
glycosylation leads to a constitutively active kinase activity of the receptor. In pancreatic β-
cells, an increase in O-linked glycosylation results in an increased β-cell apoptosis (42). 
Downstream of the insulin receptor, an increase in O-linked glycosylation leads to 
decreased phosphorylation of key insulin signaling molecules, insulin receptor substrate 1 
(IRS1) and 2 (IRS2), Akt and FOXO1a (42). These data demonstrate that glycosylation is a 
key regulator of insulin receptor function. Taken together with the observation that the 
glycemic state of the cell can modulate the pattern of glycosylation of the receptor (40, 43), 
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these data suggest that insulin receptor activity is dynamically regulated within insulin 
target cells and is sensitive to the metabolic state of the cell. 
In addition to the insulin receptor, insulin signaling molecules have been found to be 
regulated by glycosylation. Specifically, IRS-1 and β-catenin, two important downstream 
effectors of insulin receptor activation, are known to be glycosylated. Furthermore, it is 
thought that shunting of glucose metabolism through the hexosamine biosynthetic pathway 
leads to a general increase in O-linked glycosylation of nuclear and cytoplasmic proteins 
through increased substrate for O-linked N-acetylglucosamine transferase (41). Increased 
glycosylation of IRS and β-catenin and insulin receptor have been linked with decreased 
phosphorylation and activity of these key metabolic enzymes. The end result of this process 
is loss of cellular insulin sensitivity (41). 
5. Glycosylation in receptor pharmacology 
5.1. Gonadotropins 
It is now well documented that most GPCRs have the capability of signaling via multiple 
pathways in a given cell type. For many years, this hypothesis was poorly understood and 
was thought to be an artifact of recombinant cell systems. With the recent development of 
allosteric agonists, antagonists and modulators to GPCRs, more light has been shed on this 
concept; e.g., direct targeting of specific signaling pathways has been demonstrated for 
various ligands (4, 44). This phenomenon has most recently been termed, biased signaling. 
Simply put, the concept of biased signaling describes the ability of ligands to direct specific 
and distinct biological responses via activation of select signaling pathways in a ligand-
specific manner (4). There are many receptors that are known to associate with multiple 
naturally occurring ligands. The gonadotropins, LH and FSH are excellent examples of this 
phenomenon. Since varying glycosylation of gonadotropin isoforms is known to alter their 
physicochemical properties, one can consider gonadotropin isoforms as different ligands 
with potentially subtle, but unique association with their cognate receptors (4, 24). In 
addition, interaction of these diverse ligands with the receptor would result in multiple 
ligand-receptor conformations, which in turn lead to the observed activation of differing 
biological signaling pathways for LH, hCG and FSH (13, 45, 46). Thus, it has been suggested 
that gonadotropin isforms are naturally occurring biased agonists for their receptors (4, 24).  
The molecular basis for biased agonism lies in the stabilization of conformation(s) of the 
receptor which increases the affinity of the biased agonist-receptor complex for  a distinct 
and specific signaling pathway over another (44). Since GPCRs primarily utilize G proteins 
as signal transducers, biased agonism would imply ligand-dependent preference of the 
ligand-receptor complex for a specific G-protein over another. Since GPCR signaling is not 
exclusive via G-proteins, biased agonism is not restricted to G-protein signaling, and recent 
descriptions of biased ligand-mediated activation of non-G-protein-dependent signaling of 
GPCRs have appeared, such as is the case with β-arrestin signaling.  
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Figure 2. Glycosylated variants of gonadotropins are biased agonists at their receptors. Gonadotropins 
are secreted into the blood as isoforms that vary in the degree of complexity of glycosylation. Variations in 
glycosylation has been shown to be important to plasma half-life and receptor binding. It is now 
appreciated that these isoforms also impact the biological activity of the gonadotropins (4). In the case of 
FSH (depicted), glycosylated variants stabilize different conformations of the receptor-ligand complex. 
This leads to different affinities of the receptor-ligand complex for association with G proteins. Highly 
complex, terminally sialylated FSH induces activation of Gs signaling pathways. Less complex 
glycosylation associated with terminal mannose leads to activation of both Gs and Gi signaling pathways. 
Deglycosylated FSH activates the Gi signaling pathway. Since the FSHR is also know to affect other 
signaling pathways, such as Gq, these isoforms may also differentially activate Gq signaling as well. 
For many years, FSH has been used as a model to understand the role of glycosylation in 
determining glycoprotein hormone function. Several years ago, we noted that differently 
glycosylated variants of hFSH could induce activation of both the Gs and Gi signaling 
pathways (24, 47). The phenomenon appeared as a bell-shaped concentration-response 
curve in in vitro assay systems for less glycosylated insect cell expressed hFSH (BV-hFSH). 
Pertussis toxin was found to block the down-turn in the dose-response relationship, 
indicating that the descending phase of the curve for the BV-hFSH was due to activation of 
Gi at higher concentrations of the hormone. These pharmacological relationships had been 
described previously for other receptors such as the catacholamines and adenosine receptors 
(48, 49). In the case of the insect cell expressed hFSH (BV-hFSH), glycosylation was 
terminated at short branched mannose residues, and the protein displayed a more basic 
migration pattern in chromatofocusing (Arey, unpublished data). Subsequent experiments 
using an ADP-ribosylation assay, along with immunoprecipitation and Western blotting 
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of specific G-proteins, revealed that these pharmacological responses were definitively 
associated with activation of specific G-proteins (50). Taken together with in vivo effects of 
the different FSH preparations (4), these data demonstrate that the activities observed in 
signaling are directly translated into organ growth responses and illustrate the ability of 
the biased ligand (e.g., BV-hFSH) to elicit a different response pattern than that of the 
native ligand (phFSH) (Figure 2). Interestingly, similar glycosylation-dependent signal 
biasing has been noted for other secreted glycoproteins [e.g. IL22 and BMP6, (51, 52)] 
including LH/hCG (53, 54). Ligand glycosylation has also been suggested to be required 
for LH/hCG receptor dimerization (53, 55). In the case of BMP6, detailed mutagenesis 
around key asparagine residues has revealed the importance of glycosylation in 
interactions with its receptor (52). In the case of IL22, a single fucose residue on Asn54 
was shown to be required for full efficacy of the cytokine at its receptor. It is worth 
mentioning that the binding kinetics of the receptor were altered by more complex 
glycosylation at this site (51). Similar but more dramatic effects of glycosylation on 
binding kinetics have also been noted for erythropoeitin (56). These examples lay the 
foundation for the concept that a variety of related natural ligands talk to the receptor by 
inducing specific receptor conformations and that glycosylation plays a role in aiding in 
this stabilization, thus transducing specific signals that are unique to a given 
physiological state. Similar activities were ultimately discovered for other GPCRs (57). 
Therefore, from a mechanistic viewpoint, there is strong support for the notion that 
alteration of the glycosylation pattern on glycoprotein hormones leads to biased ligands 
that direct activation of one signaling pathway over another. The data support the notion 
that more basic isoforms of the gonadotropins bind with a higher affinity but are “less” 
bioactive. Therefore, different glycosylated variants may interact with the receptor in 
subtle, but unique ways to result in different signaling and biological responses . Overall, 
the data indicate that receptor signaling has evolved to convey complex regulatory signals 
in response to varying ligands which are dynamically adjusted to accommodate to 
external/internal influences and ultimately maintain homeostasis. 
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